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Dwyer

FOR IMMEDIATE RELEASE

Dr. Carl L. Larson, director of the Stella Duncan Memorial Institute at
Montana State University, has received a U. S. Public Health Service Research
Career Award to continue basic research on tuberculosis, MSU officials announced.
The current award from the National Institute of Allergy and Infectious
Diseases, effective December 1, will provide $18,717 for the coming year and is
renewable for an additional year.
$83,105 in

The grant supplements a USPHS award of

1963 in support of Dr. Larson's work.

Dr. Larson, in collaboration with Dr. Edgar Ribi of the Rocky Mountain
Laboratory in Hamilton, is working to perfect a vaccine that will give immunity
to tuberculosis without producing sensitivity.

Severed, months ago he and his

colleague succeeded in producing a killed vaccine that proved effective and
much less sensitizing than BCG vaccine in tests on laboratory animals.

BCG

has the disadvantage of being a live vaccine that produces a positive skin
reaction to tuberculosis, Dr. Larson explained.
In sounding a note of cautious optimism about promising development of
the research, Dr. Larson stressed that TB researchers speak of optimism in
terms of years, not months.

Their vaccine will not be tested on humans for

some time yet, but Drs. Larson and Ribi are encouraged by their results so far.
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